Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04274465 · ClinicalTrials.gov registry record
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia
A clinical trial, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- 145
- Enrollment target
NCT04274465: Completed study, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT04274465 is a clinical trial that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04274465 has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
The purpose of this study is to see if circulating HPV DNA (cHPVDNA) can be used as a noninvasive biomarker for cervical intraepithelial neoplasia (CIN) 2-3 in hopes of reducing procedures and costs for patients, as well as personalize their treatment plan.
Primary Outcome
We will quantify cHPVDNA levels in blood plasma from patients with normal screening, CIN 1, and CIN 2-3 cervical disease prior to treatment.
Interventions
- DIAGNOSTIC_TEST digital PCR (dPCR) assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2024-07-15 |
What the finished NCT04274465 record still lists
NCT04274465 is an observational study that tracks outcomes without assigning an intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which digital PCR (dPCR) assay is the first listed.
NCT04274465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04274465 about?
NCT04274465 is a clinical study titled "Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia". The purpose of this study is to see if circulating HPV DNA (cHPVDNA) can be used as a noninvasive biomarker for cervical intraepithelial neoplasia (CIN) 2-3 in hopes of reducing procedures and costs for patients, as well as personalize their treatment plan.
What is the current status of trial NCT04274465?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2020-02-26. Estimated completion is 2024-07-15.
What interventions are being tested in trial NCT04274465?
The interventions under investigation include: digital PCR (dPCR) assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04274465?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI